Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial

Issaka Sagara 1 Abdoul Habib Beavogui 2 Issaka Zongo Issiaka Soulama 3 Isabelle Borghini-Fuhrer Bakary Fofana 4 Aliou Traore Nouhoum Diallo Hamadoun Diakite Amadou Togo 5 Sekou Koumare Mohamed Keita Daouda Camara Anyirékun Somé Aboubacar Coulibaly Oumar Traoré 6 Souleymane Dama 7 Siaka Goïta 8 Moussa Djimde 7 Amadou Bamadio 7 Niawanlou Dara 7 Hamma Maiga 7 Bouran Sidibe Francois Dao Moctar Coulibaly Mohamed Alhousseini 7 Hamidou Niangaly 9 Boubou Sangare Modibo Diarra Samba Coumare Moïse Kabore San Maurice Ouattara Aissata Barry Désiré Kargougou Amidou Diarra 3 Noelie Henry Harouna Soré Edith Bougouma 3 Ismaila Thera Yves Compaore Colin Sutherland 10 Malick Minkael Sylla Frederic Nikiema Mamadou Saliou Diallo Alassane Dicko 1 Stéphane Picot 11 Steffen Borrmann 12 Stephan Duparc Robert Miller 13 Ogobara Doumbo 7 Jangsik Shin José Pedro Gil 14 Anders Bjorkman 15 Jean-Bosco Ouédraogo 16 Sodiomon Sirima 3 Abdoulaye Djimde 17
Document type :
Journal articles
Complete list of metadatas

https://hal-udl.archives-ouvertes.fr/hal-02136477
Contributor : Umr5246 Icbms <>
Submitted on : Wednesday, May 22, 2019 - 10:26:09 AM
Last modification on : Saturday, May 25, 2019 - 1:26:35 AM

Links full text

Identifiers

Citation

Issaka Sagara, Abdoul Habib Beavogui, Issaka Zongo, Issiaka Soulama, Isabelle Borghini-Fuhrer, et al.. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. The Lancet, Elsevier, 2018, 391 (10128), pp.1378-1390. ⟨10.1016/S0140-6736(18)30291-5⟩. ⟨hal-02136477⟩

Share

Metrics

Record views

47